AA
EPIX

ALPS Advisors’s ESSA Pharma EPIX Stock Holding History

ALPS Advisors’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,052
Closed -$44K – 1044
2022
Q3 		$44K Sell
24,052
-2,088
-8% -$5.5K ﹤0.01% 1038
2022
Q2 		$82K Buy
+26,140
New +$146K ﹤0.01% 1027

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

ALPS Advisors's EPIX Position: Q4 2022 in Review

ALPS Advisors sold out of ESSA Pharma (EPIX) in Q4 2022, closing a stake of 24,052 shares — an estimated $44K sold.

ALPS Advisors first reported a position in EPIX in Q2 2022 and held it in 2 quarters. The position peaked at $82K in Q2 2022. 45 funds tracked by Wall St. Rank hold EPIX as of Q4 2022.

  • ALPS Advisors reported no remaining ESSA Pharma position as of Q4 2022 after selling out during the quarter.
  • ALPS Advisors sold 24,052 ESSA Pharma shares in Q4 2022, an estimated $44K.
  • ALPS Advisors first reported a position in ESSA Pharma in Q2 2022 and held it in 2 quarters.
  • ALPS Advisors's ESSA Pharma position peaked at $82K in Q2 2022.
  • 45 funds tracked by Wall St. Rank held ESSA Pharma as of Q4 2022.

Based on ALPS Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.